Holley Sirois Physical Therapist Medicare: Medicare Enrolled Practice Location: 392 Main St, Waterboro, ME 04087 Phone: 207-247-3216 |
Massabesic Health Resources Pa Physical Therapist Medicare: Medicare Enrolled Practice Location: 392 Main St, Waterboro, ME 04087 Phone: 207-247-3216 Fax: 207-247-3217 |
Hayes A Sweeney, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 392 Main St, Waterboro, ME 04087 Phone: 207-247-3216 Fax: 207-247-3217 |
Andrew J. Toothaker, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 392 Main St, Waterboro, ME 04087 Phone: 207-247-3216 Fax: 207-247-3217 |
Mrs. Whitney G Lailer, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 392 Main St., Waterboro, ME 04087 Phone: 207-247-3216 Fax: 207-247-3217 |
James Stevenson, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 392 Main St, Waterboro, ME 04087 Phone: 207-247-3216 Fax: 207-247-3217 |
Adam Robert King Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 392 Main Street, Waterboro, ME 04087 Phone: 207-347-3216 Fax: 207-347-3217 |
News Archive
A leader in healthcare, Henry Ford Health System will introduce at its hospitals and pharmacies "The Pill Timer," representing a "breakthrough" designed to improve treatment outcomes and reduce adverse drug events often resulting in costly hospital admissions due to poor medication management by patients.
Leukemia stem cells are considered to be the starting point of leukemia; their elimination is a basic prerequisite for a successful long-term therapy. Scientists at Heidelberg University Hospital, the Heidelberg Institute for Stem Cell Technology and Experimental Medicine at the German Cancer Research Center, the German Cancer Research Center and the European Molecular Biology Laboratory have now obtained research funding of €2.45 million from the German Federal Ministry of Education and Research as part of the junior research alliance LeukoSyStem.
Amid the growing recognition that only a small fraction of the cells and genes in a typical human being are human, scientists are suggesting a revolutionary approach to developing new medicines and treatments to target both the human and non-human components of people. That's the topic of an article, which reviews work relating to this topic from almost 100 studies, in ACS' Journal of Proteome Research.
ADVENTRX Pharmaceuticals, Inc. today announced the launch of its redesigned and updated corporate website,www.adventrx.com. The new website features clinician videos, patient resources, and important news pertaining to sickle cell disease and ADVENTRX's lead product candidate, ANX-188 (purified poloxamer 188).
› Verified 6 days ago